The development of drug resistance is anticipated to open up new avenues for the Anti-Malarial Drugs Market

by

The global Anti-Malarial Drugs Market is estimated to be valued at US$ 989.7 Mn or Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Anti-malarial drugs are essential medicines used for the treatment and prevention of malaria. Malaria remains endemic in many developing tropical regions with resistance to existing anti-malarials posing a key challenge.

Market key trends:
One of the major trends in the anti-malarial drugs market is the development of new drugs to counter growing drug resistance. Malaria parasites have shown resistance to commonly used anti-malarials like chloroquine and sulfadoxine-pyrimethamine. This has necessitated research into developing novel anti-malarial compounds with new mechanisms of action. Some of the new drugs in clinical trials include OZ439 from Monash University that targets the parasite mitochondria, and SJT-264 from Sanofi that inhibits protein synthesis. If successful, these could help overcome multi-drug resistance and reduce the malaria burden.
Market key trends:
One of the key trends in the anti-malarial drugs market is the development of new drugs to counter widespread drug resistance. Malaria parasites have been developing resistance to commonly used anti-malarial drugs like chloroquine. This has necessitated the development of new drugs with novel mechanisms of action. Many companies are investing in R&D to develop drugs that can effectively treat resistant strains of malaria.

SWOT Analysis
Strengths: Wide range of treatment options available; Increasing government support and funding for malaria control and eradication programs.
Weaknesses: Emergence of drug resistance; Lack of vaccines for malaria.
Opportunities: High unmet needs in developing countries; Developing innovative drug delivery systems to improve patient compliance.
Threats: Changing environmental conditions contributing to spread of malaria; Potential side effects of anti-malarial drugs.

Key Takeaways
The global anti-malarial drugs market is expected to witness high growth, exhibiting CAGR of 4.5% over the forecast period, due to increasing government initiatives and funding for malaria control and eradication programs globally.

Regionally, the market in Africa dominates currently due to high burden of malaria cases in the region. According to WHO, over 90% of global malaria deaths occur in Africa, with highest cases reported in the Democratic Republic of the Congo, Nigeria and Mozambique.

Key players operating in the anti-malarial drugs market include Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd. Major companies are focused on developing novel drugs to counter resistance and achieve sustainable malaria control.